On March 22, 2021, Noile-Immune Biotech Inc. closed the transaction. The company has amended the terms and received approximately ¥2,380,000,000 in the transaction. The transaction included participation from new investors Binex Holdings Co., Ltd., Shibuya Corporation (TSE:6340), The Dai-ichi Life Insurance Company, Limited, Healthcare Innovation Investment Limited Partnership, and KD Bio Investment Fund 4, and existing investor BiGEN Co., Ltd. The company has received ¥1,380,001,197 in its second tranche.